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report their synthesis, spectroscopic characterization and 
the pharmacological profile of Schiff base analogous 
5-fluoroindolin 2-one. The synthesized compounds 
were screened for their analgesic, anti-inflammatory, and 
ulcerogenic index activities. 
MATERIALS AND METHODS
Chemistry
Melting points (mp) were taken in open capillaries on Thomas 
Hoover melting point apparatus and are uncorrected. The 
IR spectra were recorded in film or in potassium bromide 
disks on a Perkin-Elmer 398 spectrometer. The 1H spectra 
were recorded on a DPX-300 MHz Bruker FT-NMR 
spectrometer. The chemical shifts were reported as parts 
per million (δ ppm) tetramethylsilane (TMS) as an internal 
standard. Mass spectra were obtained on a JEOL-SX-102.
INTRODUCTION
Compounds with the structure of -C=N- (azomethine 
group) are known as Schiff bases, which are usually 
synthesized from the condensation of primary amines and 
active carbonyl groups. Schiff bases are important class of 
compounds in medicinal field. Ample studies demonstrated 
the biological applications including antibacterial,[1-6] 
antifungal,[3-6] and antitumor activities.[7,8] Similarly, indole 
derivatives are known to possess a variety of biological 
activities such as CNS depressant, anticancerous, 
antimicrobial, antihistaminic, anticonvulsants, and many 
others.[9] Many naturally occurring products contain 
the indole skeleton as a backbone of their structural 
frameworks.[10] 
Based on the above-mentioned properties of Schiff 
bases and indole analogous, in our present study we 
Pharmaceutical Chemistry
Synthesis and Pharmacological Evaluation of Novel Schiff Base 
Analogues of 3-(4-amino) Phenylimino) 5-fluoroindolin-2-one
R Nirmal, CR Prakash1, K Meenakshi, P Shanmugapandiyan
Department of Pharmaceutical Chemistry, Balaji Institute of Pharmacy, Laknepally (V), Narsampet (M), 
Warangal, Andhra Pradesh – 506 331, 1DCRM Pharmacy College, Inkollu (V), Prakasam (D) 
Andhra Pradesh– 523 167, India
Address for correspondence: Dr. Nirmal R; E-mail: nirmalpharma@gmail.com
ABSTRACT
In our study, a series of novel 3-(4-(benzylideneamino) phenylimino) 4-fluoroindolin-2-one derivatives were 
synthesized and characterized by spectral (I.R, 1H NMR, mass) and elemental analysis. The title compounds 
(N1-N10) were evaluated for analgesic, anti-inflammatory, and ulcerogenic index activities. Results displayed that 
compound N3 exhibited significant analgesic activity. Among the title compounds studied, N2, N3, and N8 exhibited 
significant anti- inflammatory activity comparable to reference standard diclofenac sodium. Interestingly, the test 
compounds showed only mild ulcerogenic side effect when compared to aspirin.   
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instrument using fast atom bombardment (FAB 
positive). Elemental analysis was performed on a Perkin-
Elmer 2400 C, H, N analyzer and values were within the 
acceptable limits of the calculated values. The progress 
of the reaction was monitored on readymade silica 
gel plates (Merck) using chloroform/methanol (9:1) 
as a solvent system. Iodine was used as a developing 
agent. Spectral data (IR,  1H NMR and mass spectra) 
confirmed the structures of the synthesized compounds 
and the purity of these compounds was ascertained by 
microanalysis. Elemental (C, H, and N) analysis indicated 
that the calculated and observed values were within the 
acceptable limits (±0.4%). All chemicals and reagents 
were obtained from Aldrich (USA), Lancaster (UK), or 
Spectrochem Pvt. Ltd (India) and were used without 
further purification.
Synthesis of 5- fluoro imesatins (4)
Chloral hydrate (0.054 moles) in water (120 ml) was 
prepared. To this 4-fluoro aniline (1) (0.158 mole) and 
sodium sulfate (0.05mol) was added dropwise for 30 
min with stirring and finally aqueous hydroxylamine 
hydrochloride (50 ml) was added gradually keeping 
the reaction mixture was heated in about 45 min. 
During the heating period, some crystals of 4-fluoro 
isonitrosoacetanilide (2) separates out. The solid obtained 
was filtered, washed with water, dried and recrystallized 
from ethanol. Concentrated H2SO4 was added gradually 
to the resulting compound (2) and boiled for 10 min. 
The reaction mixture was then poured into ice water and 
the 5-fluoroisatin (3) filtered and purified. 4-amino aniline 
(0.01 moles) and the above prepared 5-fluoroisatin (3) were 
dissolved in warm ethanol and refluxed for 30 min. After 
standing for approximately 24 h at room temperature, 
the 5-fluoroimesatins (4) were separated by filtration and 
recrystallized from warm ethanol. Yield = 83%, mp 260-
262 °C. IR (KBr) cm -1: 3220 (NH), 1675 (C = O); 1H NMR 
(CDCl3): δ 7.15-8.74 (m, 8H, Ar-H), 10.71 (s, 1H, NH); MS 
(m/z) 237 (M+). Anal. Calcd for C14H11N3O: C, 70.87, H, 
4.67; N, 17.71. Found: C, 70.83, H, 4.66, N, 17.72.
 General synthetic procedure for compounds (N1- N10)
A mixture of 5-fluoro imesatin (4) (0.01 moles) and 0.01 
moles of appropriate ketone/aldehyde was dissolved in 
30 ml of ethanol [Scheme 1]. Then refluxed for 8 h and 
kept aside. The solid obtained was filtered, washed with 
water, dried under high vacuum, and recrystallized from 
chloroform/benzene (25:75) mixture. The physical and 
spectral data of the synthesized compounds are presented 
in Tables 1 and 2.
Pharmacology
The synthesized compounds were evaluated for analgesic, 
anti-inflammatory, and ulcerogenic index. One-way 
analysis of variance (ANOVA) was performed to ascertain 
the significance of all the exhibited activities. The test 
compounds and the standard drugs were administered in 
the form of a suspension (1% carboxymethyl cellulose as a 
vehicle) by oral route for analgesic and anti-inflammatory but 
for ulcerogenicity studies by intraperitoneally as suspension 
in 10% v/v Tween-20. Each group consisted of six animals. 
The animals were procured from the C. L. Baid Metha 
College of pharmacy, Chennai, and were maintained in 
colony cages at 25 ±2 °C, relative humidity of 45-55%, under 
a 12-h light and dark cycle; they were fed standard animal 
feed. All the animals were acclimatized for a week before 
use. The Institutional Animal Ethics Committee approved 
the protocol adopted for the experimentation of animals.
Analgesic activity
The analgesic activity was performed by tail-flick technique 
using Wistar albino mice (25-35 g) of either sex selected by 
the random sampling technique.[13,14] Diclofenac sodium at 
a dose level of 10 mg/kg and 20 mg/kg was administered 
orally as reference drug for comparison. The test compounds 
at two dose levels (10, 20 mg/kg) were administered orally. 
The reaction time was recorded at 30 min, 1, 2, and 3 h 
after the treatment, and cut-off time was 10 s. The percent 
analgesic activity (PAA) was calculated by the following 
formula, where T1 is the reaction time (s) before treatment, 
















Anti-inflammatory activity was evaluated by carrageenan-
induced paw edema test in rats.[15] Diclofenac sodium 
10, 20 mg/kg was administered as a standard drug for 
comparison. The test compounds were administered at 
two dose levels (10 mg/kg, 20 mg/kg). The paw volumes 
were measured using the mercury displacement technique 
with the help of a plethysmograph (Model PLYAN; Buxco, 
USA) immediately before and 30 min, 1, 2, and 3 h after 
carrageenan injection. The percent inhibition of paw edema 
was calculated using the following formula. 
Percent inhibition I = 100 [1- (a-x) / (b-y)]
Where x is the mean paw volume of rats before the 
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Scheme 1: Synthetic scheme for the title compounds N1 – N10
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Table 1: Physicochemical data of 3-(4-amino) phenylimino)-5-fluoroindolin-2-one (N1-N10)
Compounds Molecular formula Molecular weight2 Yield (%) M.p[0C]
N1 c18H16FN3O 309 65 224-226
N2 c19H18FN3O 323 82 243-245
N3 c19H18FN3O 323 78 262-264
N4 c21H18FN3O 347 87 247-249
N5 c22H16FN3O 357 65 232-234
N6 c21H14FN3O 343 78 253-255
N7 c22H16FN3O2 373 75 255-257
N8 c21H13FN4O3 388 69 234-236
N9 c21H13FN3O 377 82 242-244
N10 c21H14FN3O2
359 74 260-262J Young Pharm Vol 2 / No 2  165
administration of carrageenan and test compounds or 
reference compound (test group), a is the mean paw volume 
of rats after the administration of carrageenan in the test 
group (drug treated), b is the mean paw volume of rats after 
the administration of carrageenan in the control group, y 
is the mean paw volume of rats before the administration 
of carrageenan in the control group.
Evaluation of ulcerogenicity index
Ulceration in rats was induced as described by Goyal 
et al. Albino rats of Wistar strain weighing 150-200 
g of either sex were divided into various groups 
each of six animals.  [16] Control group of animals was 
administered only with 10% v/v Tween 80 suspension 
intraperitonially. One group was administered with 
aspirin (German Remedies) intraperitoneally at a dose 
of 200 mg/kg once daily for 3 days. The remaining 
group of animals was administered with test compounds 
intraperitoneally at a dose of 20 mg/kg. On fourth day, 
Pylorus was ligated as per the method of Shay et al.[17] 
Animals were fasted for 36 h before the pylorus ligation 
procedure. Four hours after the ligation, animals were 
sacrificed. The stomach was removed and opened along 
with the greater curvature. Ulcer index was determined 
by the method of Ganguly and Bhatnagar.[18]
RESULTS AND DISCUSSION
Chemistry
The key intermediate 5-fluoroimesatin (4) was prepared by 
reacting aniline (1) with chloral hydrate and hydroxylamine 
hydrochloride in sodium sulfate to give isonitrosoacetanilide 
(2), which was cyclized in the presence of concentrated 
sulfuric acid to afford the isatin (3). Compound 3 on 
reflux with 4-amino aniline in ethanol yielded the desired 
4-fluoro-imesatin (4) in good yield (83%). The IR spectrum 
of compound (4) show intense peaks at 3220 cm-1 for 
amino (NH), 1675 cm -1 for carbonyl (C=O) stretching. 
1H NMR spectra of compound (4) showed a multiplet 
at δ 7.15- 8.74 for aromatic (7H) protons and a singlet 
at δ 8.71 indicating the presence of NH. Data from the 
elemental analyses have been found to be in conformity 
with the assigned structure. Furthermore, the molecular 
ion recorded in the mass spectrum is also in agreement 
with the molecular weight of the compound. Data from 
the elemental analyses and molecular ion recorded in the 
mass spectra further confirmed the assigned structure.
The Schiff analogous of 3-(4-substituted amino)
phenylimino)-5-fluoroindolin-2-one (N1- N10) were obtained 
by the condensation of amino group of 3-(4- amino) phenyl 
imino)-5-fluoroindolin-2-one (4) with a variety of alkyl and 
aryl ketones. The formation of title compounds [Scheme 1] 
is indicated by the disappearance of peak due to NH2 of the 
starting material in IR and 1H NMR spectrum [Table 2] of 
all the compounds (N1-N10). The IR and 1H NMR spectrum 
of these compounds showed the presence of peaks due 
to (N =CRR1) carbonyl (C=O), NH and aryl groups. The 
mass spectra of the title compounds are in conformity 
with the assigned structure. The mass spectrum of these 
compounds showed molecular ion peaks corresponding to 
their molecular formulae [Table 1]. A common peak at m/z 
145 corresponding to indolin-2-one moiety appeared in all 
mass spectra of compounds (N1-N10). Elemental (C, H, N) 
analysis satisfactorily confirmed elemental composition and 
purity of the synthesized compounds.
Pharmacology
Test for analgesic activity was performed by tail-flick 
technique using Wistar albino mice. The results of 
analgesic activity indicate that test compounds exhibited 
moderate analgesic activity at 30 min of reaction time; 
the activity increased at 1 h, further it reached to peak 
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Table 2: NMR and IR spectral data of the novel synthesized compounds (N1-N10)
Compound 
Code
IR (cm-1) (KBr) 1H NMR (CDCl3) δ ppm
NH C=O C=N
N1 3290 1687 1614 1.2-1.3 (q, 2H, CH2CH3), 1.5-1.6 (t, 3H, CH2CH3), 7.3-8.0 (m, 7H, Ar-H), 8.3 (s, 1H, NH).
N2 3288 1675 1611 1.0-1.2 (m, 4H, (CH2CH3)2), 1.7-1.9 (m, 6H, (CH2CH3)2), 7.4-8.1 (m, 7H, Ar-H), 8.2 (s, 1H, NH).
N3 3275 1685 1610 0.9-1.0 (t, 2H, CH2CH2CH3), 1.2-1.4 (sext, 2H, CH2CH2CH3),1.7-1.8 (t, 3H, CH2CH2CH3), 2.4 (s, 3H, 
CH3), 7.0-7.7 (m, 8H, Ar-H), 8.2 (s, 1H, NH).
N4 3289 1688 1615 1.1-1.9 (m, 10H, cyclohexanyl), 7.0-7.7 (m, 7H, Ar-H), 8.5 (s, 1H, NH).
N5 3278 1682 1617 1.5 (s, 3H, CH3), 7.1-8.3 (m, 12H, Ar-H), 8.6 ( s, 1H, NH).
N6 3292 1685 1615 6.2 (s, 1H, CH), 7.1-8.2 (m, 12H, Ar-H), 8.5 ( s, 1H, NH).
N7 3286 1676 1612 2.7-2.8 (s, 3H, OCH3), 6.1 (s, 1H, CH), 7.0-8.2 (m, 11H, Ar-H), 8.6 (s, 1H, NH).
N8 3292 1680 1619 6.4 (s, 1H, CH), 7.2-8.3 (m, 11H, Ar-H), 8.7 (s, 1H, NH).
N9 3294 1668 1610 6.2 (s, 1H, CH), 7.0-8.1 (m, 11H, Ar-H), 8.3 ( s, 1H, NH).
N10 3287 1679 1614 5.7 (s, 1H, Ar-OH). 6.4 (s, 1H, CH), 7.2-8.3 (m, 11H, Ar-H), 8.5 (s, 1H, NH).166   J Young Pharm Vol 2 / No 2
Table 4:  Percent anti-inflammatory activity of synthesized compounds Percent anti-inflammatory activity of 
synthesized compounds (carrageenan-induced paw edema test in rats)
Paw edema test in rats). Dose (mg/kg) Percent anti-inflammatory activity
30 min  1h 2h 3h
N1 10 39 ± 1.25* 45 ± 1.32* 52 ± 1.65* 32 ± 1.96*
20 44 ± 1.36** 52 ± 1.96** 58 ± 1.32** 37 ± 1.45*
N2 10 42 ± 1.25** 50 ± 1.38* 53 ± 1.15** 45 ± 1.68*
20 51 ± 1.44** 57 ± 1.72** 62 ± 1.26** 54 ± 1.67*
N3 10 49 ± 1.75** 54 ± 1.82** 60 ± 1.35** 43 ± 1.96*
20 54 ± 1.59*** 62 ± 1.27*** 66 ± 1.24*** 52 ± 1.45*
N4 10 38 ± 1.82* 50 ± 1.24* 55 ± 1.15* 35 ± 1.76*
20 45 ± 1.36* 56 ± 1.83** 60 ± 1.19** 44 ± 1.65*
N5 10 39 ± 1.56* 46 ± 1.88* 52 ± 1.65* 32 ± 1.26*
20 45 ± 1.73* 54 ± 1.95** 59± 1.36** 42 ± 1.48*
N6 10 37 ± 1.67* 42 ± 1.42* 49 ± 1.58* 36 ± 1.96*
20 46 ± 1.48* 55 ± 1.76** 59 ± 1.93** 38 ± 1.47*
N7 10 36 ± 1.74* 42 ± 1.72* 45 ± 1.55* 33 ± 1.69*
20 44 ± 1.76** 55 ± 1.78 ** 58 ± 1.66** 41 ± 1.48*
N8 10 40 ± 1.65* 44 ± 1.53* 48 ± 1.74* 36 ± 1.36*
20 49 ± 1.46* 52 ± 1.92** 56 ± 1.16* 39 ± 1.48*
N9 10 38 ± 1.82* 44 ± 1.32* 48 ± 1.99* 36 ± 1.72*
20 44 ± 1.68* 52 ± 1.16** 55 ± 1.68** 38 ± 1.32*
N10 10 43 ± 1.55* 49 ± 1.72* 54 ± 1.52* 39 ± 1.92*
20 48 ± 1.56* 54 ± 1.65** 58 ± 1.16** 42 ± 1.43*
Control 5.1 ± 0.35 6.1 ± 0.42 5.7 ± 0.30* 3.2 ± 1.56*
Diclofenac 10 32 ± 0.69* 38 ± 1.42* 39 ± 1.97* 33 ± 0.93*
20 45 ± 1.65** 52 ± 0.96*** 60 ± 1.52*** 39 ± 1.13*
aEach value represents the mean ± SD (n = 6). Significance levels *P < 0.05, **P < 0.01 and ***P< 0.001 as compared with the respective control.
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Table 3: Percent analgesic activity of synthesized compounds (tail-flick technique)
Compounds Dose (mg/kg) Percent analgesic activity
30 min  1h 2h 3h
N1 10 47 ± 1.25* 51 ± 1.32* 53 ± 1.15* 31 ± 1.96*
20 54 ± 1.36** 58 ± 1.96** 60 ± 1.16*** 47 ± 1.45*
N2 10 50 ± 1.25** 56 ± 1.32** 60 ± 1.15** 45 ± 1.68*
20 57 ± 1.44** 60 ± 1.90** 64 ± 1.26*** 50 ± 1.67*
N3 10 55 ± 1.75*** 62 ± 1.82*** 64 ± 1.35** 46 ± 1.96*
20 62 ± 1.59*** 66 ± 1.77*** 69 ± 1.24*** 52 ± 1.45*
N4 10 48 ± 1.28* 52 ± 1.52* 54 ± 1.15* 35 ± 1.76*
20 55 ± 1.36* 57 ± 1.66** 59 ± 1.19** 44 ± 1.65*
N5 10 44 ± 1.76* 49 ± 1.88* 52 ± 1.55* 32 ± 1.26*
20 52 ± 1.33* 55 ± 1.95** 59 ± 1.36** 42 ± 1.48*
N6 10 37 ± 1.87* 46 ± 1.42* 49 ± 1.15* 36 ± 1.96*
20 49 ± 1.83* 54 ± 1.76** 59 ± 1.18** 43 ± 1.47*
N7 10 34 ± 1.74* 43 ± 1.72* 45 ± 1.45* 29 ± 1.69*
20 47 ± 1.96** 52 ± 1.67** 56 ± 1.36** 44 ± 1.48*
N8 10 39 ± 1.75* 46 ± 1.43* 48 ± 1.24* 36 ± 1.36*
20 48 ± 1.46* 51 ± 1.92** 54 ± 1.16* 39 ± 1.48*
N9 10 42 ± 1.82* 44 ± 1.72* 48 ± 1.59* 38 ± 1.72*
20 46 ± 1.68* 51 ± 1.46** 57 ± 1.18** 45 ± 1.32*
N10 10 43 ± 1.55* 46 ± 1.72* 49 ± 1.52* 38 ± 1.92*
20 48 ± 1.56* 52 ± 1.96** 58 ± 1.16** 42 ± 1.43*
Control 3 ± 0.35 5 ± 0.42 4 ± 0.50* 4 ± 1.56*
Diclofenac 10 37 ± 1.69* 43 ± 1.42* 45 ± 0.92* 33 ± 0.96*
20 46 ± 0.95* 55 ± 1.16** 62 ± 1.49*** 39 ± 1.13*
aEach value represents the mean ± SD (n = 6). Significance levels *P < 0.05, **P < 0.01 and ***P < 0.001 as compared with the respective control.J Young Pharm Vol 2 / No 2  167
level at 2 h and declining in activity was observed at 3 
h [Table 3]. Compound N3 with 1-methyl butylidene 
substituents showed good activity among the aliphatic 
groups. Replacement of 1-methylbutylidene groups with 
alkyl chain with a cycloalkyl group and an aralkyl group 
(compounds N4 and N5 respectively) leads to moderate 
decrease in activity.
Replacement of aryl group at the N-4 position (compounds 
N6, N7, and N9) also results in decreasing activity. Placement 
of electron withdrawing group at N-4 aryl ring (compounds 
N7, N8) leads to further decrease of activity when compared 
to the reference standard diclofenac sodium. 
Anti-inflammatory activity was evaluated by carrageenan-
induced paw edema test in rats. The anti-inflammatory 
activity data [Table 4] indicated that all the test compounds 
protected rats from carrageenan-induced inflammation 
moderately at 30 min of reaction time; the activity increased 
at 1 h and it reached to peak level at 2 h. Declining in 
activity was observed at 3 h. Compound N3 with 1-methyl 
butylidene substituents showed moderately more potent 
anti-inflammatory activity when compared to the reference 
standard diclofenac sodium. The compound N2 with 
1-methyl ethylidene substituents and compound N8 showed 
equipotent anti-inflammatory activity when compared to 
the reference standard diclofenac sodium. 
The ulcer index of the test compounds [Table 5] reveal 
that the compounds with open chain aliphatic substituents 
(compounds N1-N5) showed negligible ulcer index, whereas 
aryl substituents (compounds N6-N9) exhibited little 
increase in ulcer index and the aryl substituents containing 
electron withdrawing groups (compounds N7,N8, and N10) 
exhibited higher ulcer index over other test compounds. 
When compared to the reference standards aspirin (ulcer 
index 1.73 ± 0.41) and diclofenac (ulcer index 1.65 ± 0.59) 
the test compounds exhibited about 35-50% of the ulcer 
index of reference standards.
CONCLUSION
We  have  described  the  preparation  of   3-(4- 
(benzylideneamino) phenylimino) 5-fluoro-indole-2-one. 
Several of these compounds have been evaluated as 
potential anti-inflammatory, analgesic agents with negligible 
ulcer index. In conclusion, this preliminary investigation 
showed that the presence of alkyl groups exhibited more 
analgesic and anti-inflammatory activities over aryl groups 
at the N-4 position. Among the synthesized compounds 
N2 and N3 possessed the most prominent and consistent 
activity with maximum reduction of ulcerogenecity. 
Therefore, this series has opened new doors for possible 
modifications of the pharmacophoric requirements of 
NSAIDs and future exploitations.
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